Clinical TrialMay 19, 2026, 08:02 AM
Black Diamond to Present Updated Phase 2 Silevertinib Results
AI Summary
Black Diamond Therapeutics, a clinical-stage oncology company, announced it will host a webcast for investors on Thursday, May 21, 2026, at 5:30 p.m. ET. The webcast will present updated results from its ongoing Phase 2 trial of silevertinib in frontline patients with EGFR mutated non-small cell lung cancer. Silevertinib is a brain-penetrant fourth-generation EGFR MasterKey inhibitor designed to target families of oncogenic mutations.
Key Highlights
- Black Diamond Therapeutics to host an investor webcast on May 21, 2026, at 5:30 p.m. ET.
- The webcast will present updated results from the ongoing Phase 2 trial of silevertinib.
- Silevertinib is being evaluated in frontline patients with EGFR mutated non-small cell lung cancer.
- Silevertinib is a brain-penetrant fourth-generation EGFR MasterKey inhibitor.
- A replay of the webcast will be available for a limited time on the company's website.
Price Impact
More from BDTX